Ovid Therapeutics (NASDAQ:OVID) posted its earnings results on Tuesday, May 7th. The company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.04), MarketWatch Earnings reports.
NASDAQ:OVID opened at $1.59 on Friday. The company has a market capitalization of $65.39 million, a P/E ratio of -0.75 and a beta of 2.10. Ovid Therapeutics has a 1-year low of $1.55 and a 1-year high of $11.45. The company has a quick ratio of 7.78, a current ratio of 7.78 and a debt-to-equity ratio of 0.02.
Hedge funds have recently made changes to their positions in the business. Morgan Stanley lifted its position in Ovid Therapeutics by 225.6% in the first quarter. Morgan Stanley now owns 125,906 shares of the company’s stock valued at $224,000 after purchasing an additional 87,238 shares during the last quarter. Geode Capital Management LLC lifted its position in Ovid Therapeutics by 7.1% in the fourth quarter. Geode Capital Management LLC now owns 95,865 shares of the company’s stock valued at $231,000 after purchasing an additional 6,391 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Ovid Therapeutics by 11.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 87,257 shares of the company’s stock valued at $211,000 after purchasing an additional 8,995 shares during the last quarter. Hedge funds and other institutional investors own 31.73% of the company’s stock.
About Ovid Therapeutics
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Recommended Story: Determine Your Level of Risk Tolerance
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.